Abstract
Evidence suggests that N-methyl-d-aspartate receptors (NMDARs) have a relatively high affinity for agonist compared with non-NMDA receptors. Dose-response curves constructed with sustained agonist application suggest that the 50% effective concentration (EC50) for peak glutamate-evoked current at NMDARs is 1 to 10 μM, whereas that of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors is ∼500 μM. Given estimates of synaptic cleft glutamate concentration in the millimolar range, it would be expected that NMDARs would be saturated with agonist. However, studies of synaptic NMDAR responses indicate that these receptors may not be saturated during single release events at many synapses. To address this apparent contradiction, we have compared the glutamate dose-response curve for the peak NMDAR current generated by sustained glutamate application with that obtained during brief synaptic-like pulses of agonist. Our results using both recombinant and native NMDARs indicate a marked reduction in glutamate potency with reduced agonist application duration (EC50 = 100 to 200 μM with 1 ms application). A kinetic model suggested that the reduction in potency with shorter agonist application duration could be attributed to the relatively slow activation and deactivation rates of the NMDARs. Comparison of room temperature to 37°C indicated that NMDAR activation and deactivation were strongly accelerated by increased temperature. However, at 37°C, we still observed a significant increase in potency with longer agonist application duration. We propose that glutamate has a relatively lower potency at NMDARs than previously thought from agonist application under equilibrium conditions. This lower potency would account for data that shows nonsaturation of NMDARs during synaptic transmission.
Footnotes
- Received July 3, 2000.
- Accepted October 10, 2000.
-
Send reprint requests to: Dr. T.H. Murphy, Department of Psychiatry, 4N1–2255 Wesbrook Mall, Vancouver, B.C., V6T 1Z3 Canada. E-mail thmurphy{at}interchange.ubc.ca
-
This work was supported by Medical Research Council (MRC) of Canada operating Grants MT-12675 (T.H.M.) and MT-12699 (L.A.R.). T.H.M. is an MRC Scientist. J.R. holds an MRC Canada studentship. N.C. is supported by the John Wasmuth Fellowship from the Hereditary Disease Foundation.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|